This drug has emerged as a pivotal therapeutic option targeting the MAPK/ERK pathway in various malignancies, including BRAF-mutated melanoma, non-small cell lung cancer and thyroid cancer. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.